• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
analytics
SiSense Logo
March 17, 2020 by Global Pricing Innovations (GPI)
GPI makes market access more efficient with pioneering partnership with Sisense-enabled analytics platform

Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers  London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…

October 25, 2019 by Global Pricing Innovations (GPI)
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…

Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs
GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

October 21, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations is proudly attending ISPOR Europe in Copenhagen this year!

Make sure you get in touch with our Experts to find out how you can optimise your commercial potential through data analytics. For more info, contact preeti.patel@globalpricing.com

ISPOR Europe 2019, 2-6 November 2019. Copenhagen, Denmark
Novartis building
October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

September 25, 2019 by Global Pricing Innovations (GPI)
What the Beneluxa Group is aiming for next

BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…

What the Beneluxa Group is aiming for next
September 23, 2019 by Global Pricing Innovations (GPI)
With the Updated Stability Programme 2019-2022, Spanish government reinforces healthcare budget control measures

In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 27, 2019 by Global Pricing Innovations (GPI)
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns

  On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 19, 2019 by Global Pricing Innovations (GPI)
The new Pricing System in Russia will lead to price decreases for many medicines

  Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…

June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

June 4, 2019 by Global Pricing Innovations (GPI)
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation.

Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…

May 15, 2019 by Global Pricing Innovations (GPI)
New set of rules regulating medicine prices in Kazakhstan

  New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…

April 18, 2019 by Global Pricing Innovations (GPI)
New IRP rule introduced in Greece

International Reference Pricing (IRP) is constantly under the spotlight as an effective mechanism to regulate the prices of medical products. In the USA there was a concern to implement IRP in an effort to try and constrain the increased prices of drugs in…

April 8, 2019 by Global Pricing Innovations (GPI)
Harmonisation of HTA practice: Underlying methodological differences across HTA agencies that impact national list prices

By Alexandros Soumalevris, GPI     Working towards Health Technology Assessment (HTA) harmonisation There have been calls for the European Union (EU) countries, the European Parliament and other interested parties initiated in 2016 to the European Commission, to work on strengthening EU cooperation…

March 4, 2019 by Global Pricing Innovations (GPI)
Employee Spotlight – Popat Bankar

Popat Bankar Business Analyst Joined GPI Mumbai in January 2017 Up this week in our Employee Spotlight Series is our Business Analyst – Popat Bankar. Popat is apart of our fantastic team of analysts based in our office out in Mumbai. Popat sat…

September 21, 2018 by Global Pricing Innovations (GPI)
Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations  

Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…

September 15, 2017 by Global Pricing Innovations (GPI)
Pharma Pricing Experts, Global Pricing Innovation, Announce the Appointment of Mikhael Aktsyzniy to Head Technology and Development

Global Pricing Innovations (GPI) has further strengthened its technology division with the addition of Mikhael Aktsyzniy Mikhael joins GPI from Accenture as Head of Technology and Development to continue GPI’s success providing powerful pharma pricing intelligence based business services to valued clients across…

Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121